As a world-leading service provider of antibody development and generation, Creative Biolabs is ready to provide a whole series of biomarker-specific in vitro diagnostic (IVD) antibody development services. A team of experienced scientists focused on antibody development are pleased to assist you in your project in a timely and cost-effective manner. Here, we introduce our IVD antibody development services targeting epidermal growth factor (EGF) marker.

Epidermal Growth Factor (EGF) Marker

Epidermal growth factor (EGF) is a single-chain polypeptide consisting of 53 amino acid residues, including six Cys residues that form three disulfide bonds. It was first described as a secreted peptide isolated from the submaxillary glands of the adult male mouse and human urine. Studies have shown that EGF is distributed in many human tissues including submandibular gland and parotid gland. Importantly, it has the ability to stimulate the proliferation of a number of epithelial tissues by binding to its receptor, EGFR, which can be activated by several mechanisms under physiological or pathophysiological conditions.

Overview of the EGF signaling pathway. Fig.1 Overview of the EGF signaling pathway. (Sauter G, et al. 1994)

EGF Marker of Bladder Cancer

In the last decades, the incidence of human bladder cancer has increased extensively. However, it is still difficult to predict tumor progression, optimal therapy, and finally, clinical outcome through several attempts. Studies have suggested that the actions of EGF are mediated by binding to the external domain of a transmenibranous receptor (EGFR) which results in down-regulation of the receptor and stimulation of a tyrosine kinase that is an integral part of the internal domain of the receptor. Besides, it has been reported that the concentration of EGF is high in the urine of bladder cancer patients, and EGFR expression is strongly associated with the grade and stage of bladder cancer. In this case, the epidermal growth factor can be used as a potential marker for the detection and prognosis of bladder cancer.

HB-EGF Marker of Coronary Artery Disease

Coronary artery disease (CAD) is the cardiovascular disease with the symptom of angina or heartache caused by atherosclerosis. Both of these two forms of HB-EGF participate in normal physiological and pathological processes, especially for the atherosclerosis disease. Some studies have shown that increased levels of HB-EGF can be detected in the atherosclerotic regions of macrophages and smooth muscle cells and the increased level of plasma HB-EGF is associated with the incidence of coronary artery disease in human subjects.

IVD Antibody Development Services for EGF Marker

IVD antibodies are extensively used in immunodiagnostic tools for disease screening and therapeutic monitoring. Through our role as a leading antibody service provider, Creative Biolabs is well-positioned to develop high-quality EGF-specific antibodies. Besides antibody generation, Creative Biolabs also offers diagnostic immunoassay development services, including feasibility analysis, assay design, assay protocol establishment, assay optimization, and kit production.

Creative Biolabs has successfully completed numerous IVD antibody generation and development projects for clients across the globe. If you are interested in the services we provide, please don't hesitate to contact us and get a quote.


  1. Sauter G., (1994). “Epidermal‐growth‐factor‐receptor expression is associated with rapid tumor proliferation in bladder cancer.” International journal of cancer, 57(4): 508-514.

For lab research use only.

Online Inquiry

*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-357-2254
Fax: 1-631-207-8356
Heidenkampsweg 58, 20097 Hamburg, Germany
Tel: 44-207-097-1828
Follow us on:
Copyright ©2011 - 2020 Creative Biolabs.